The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

6225 SMITH AVENUE, BALTIMORE, MD 21209-3600, USA
Tel:
Work +1 410 580 3000
Fax:
Fax +1 410 580 3001
Web:
www.dlapiper.com

Brett Ingerman

Tel:
Work +1 410 580 4177
Email:
DLA Piper LLP (US)

Position

Partner; Managing Partner, Baltimore Office; Global Co-Chairman, Compliance and Governance Practice

Career

Brett Ingerman's primary areas of practice are business and commercial litigation and arbitration, with a focus on complex commercial disputes and lender liability issues.

Brett also has significant experience in corporate investigations and compliance involving criminal, quasi-criminal and administrative agencies.

Brett has designed and implemented global compliance programs for companies large and small, and focuses on providing practical compliance advice consistent with best practices and local custom.

Education

JD, University of Maryland School of Law; BA, Tufts University


United States: Dispute resolution

Corporate investigations and white-collar criminal defense

Within: Corporate investigations and white-collar criminal defense

DLA Piper LLP (US)’s nationwide practice is led by Jonathan King in Chicago and the FCPA-focused John Hillebrecht in New York. Hillebrecht represented NASDAQ-listed technology firm Net1 UEPS in an SEC and DOJ FCPA investigation, and parallel South African criminal investigation, into allegations of bribery. A longstanding client, GlaxoSmithKline engages the firm on global government and internal investigation matters, on which Washington DC’s Laura Terrell takes the lead. Also recommended are Philadelphia’s Ilana Eisenstein, Baltimore’s Brett Ingerman and Washington DC’s Matthew Graves.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to